Competitors
| NASDAQ:FULC Fulcrum Therapeutics, Inc. | 11.34 -0.19 (-1.65%) |
| NASDAQ:SLGL Sol-Gel Technologies Ltd | 14.30 -0.06 (-0.42%) |
| NASDAQ:VRCA Verrica Pharmaceuticals Inc | 12.69 0.000.00 |
Popular Screeners
TherapeuticsMD, Inc. (NASDAQ:TXMD) opened on Apr 19, 2021 at 1.17 USD and decreased by -1.69%. The intraday price range was 1.12 - 1.18 USD and eventually ended the session at 1.16 USD. The stock trade volume was 8.07 M shares. The company's 52-week range is 0.90 - 2.75 USD.
| Trading Statistics | (Market Close Apr 19, 2021) |
|---|---|
| Market Cap | 316.46 M |
| Outstanding Stock | 237.88 M |
| Dividend | 0.00 |
| Dividend Yield | 0.00 |
| EPS | -0.72 |
| YTD Change | -4.13% |
| 52 Week's Range | 0.90 - 2.75 |
| Key Ratio & Margins | (Market Close Apr 19, 2021) |
|---|---|
| Price/Earning | -3.61 |
| Price/Book Value | 9.29 |
| Price/Sales | 33.74 |
| ROA | - |
| ROE | - |
| Debt/Equity | 29.46 |
Company Self Description
TherapeuticsMD, Inc. operates as a women's health care product company. The company also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaMedMD and BocaGreenMD brands. It was founded in 2008 and is headquartered in Boca Raton, Florida, United States.
| Business Information | |
|---|---|
| TherapeuticsMD, Inc. | |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Exchange | NASDAQ |
| Key Fundamentals | (Market Close Apr 19, 2021) | |||
|---|---|---|---|---|
| TXMD | FULC | SLGL | VRCA | |
| Market Cap | 316.46 M | 311.43 M | 328.91 M | 328.23 M |
| Revenue Growth | - | - | - | - |
| Net Income Growth | - | - | - | - |
| Profit Margin | -913.10% | - | -24,963.60% | 0.00 |
| P/E Ratio | -3.61 | - | -3.34 | -12.10 |
| Price to Sales Ratio | 33.74 | - | 833.82 | 0 |
| Price to Book Ratio | 9.29 | - | 1.78 | 2.34 |
| Enterprise Value to EBITDA | -6.19 | - | -5.20 | -8.30 |
| ROA | - | - | -75.80% | -30.50% |
| ROE | - | - | -574.50% | -31.60% |
| Debt/Equity | 29.46 | - | 0.09 | 0.03 |
| Asset Turnover Ratio | 0.09 | - | 0.00 | 0 |
| Current Ratio | 4.55 | - | 13.48 | 36.80 |
| Dividend Yield | 0.00 | - | - | 0 |
in USD
| Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | |
|---|---|---|---|---|
| Revenue | 16.10 M | 16.78 M | 19.36 M | 20.14 M |
| Cost Of Revenue | 2.74 M | 2.64 M | 4.19 M | 4.51 M |
| Gross Profit | 13.36 M | 14.14 M | 15.17 M | 15.64 M |
| Selling General & Administrative Expenses | 115.99 M | 57.70 M | 51.35 M | 28.72 M |
| Research & Development | 27.30 M | 33.85 M | 53.94 M | 72.04 M |
| Operating Income | -130.22 M | -77.63 M | -90.25 M | -85.19 M |
| Net Income | -132.62 M | -76.93 M | -89.88 M | -85.08 M |
| EPS | -0.59 | -0.37 | -0.46 | -0.49 |
| Diluted EPS | -0.59 | -0.37 | -0.46 | -0.49 |
| Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | |
|---|---|---|---|---|
| Revenue | 6.08 M | 3.95 M | 5.09 M | 3.47 M |
| Cost Of Revenue | 1.25 M | 762,827.00 | 950,750.00 | 699,118.00 |
| Gross Profit | 4.83 M | 3.18 M | 4.14 M | 2.77 M |
| Selling General & Administrative Expenses | 41.39 M | 34.86 M | 35.41 M | 30.35 M |
| Research & Development | 4.96 M | 6.32 M | 6.75 M | 6.71 M |
| Operating Income | -41.64 M | -38.11 M | -38.12 M | -34.36 M |
| Net Income | -55.24 M | -39.51 M | -39.39 M | -35.61 M |
| EPS | -0.23 | -0.16 | -0.17 | -0.16 |
| Diluted EPS | -0.23 | -0.16 | -0.17 | -0.16 |
in USD
| Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | |
|---|---|---|---|---|
| Total Current Assets | 186.78 M | 139.55 M | 139.41 M | 70.68 M |
| Cash & Cash Equivalents | 161.61 M | 127.14 M | 131.53 M | 64.71 M |
| Total Assets | 211.98 M | 143.23 M | 142.47 M | 73.73 M |
| Total Current Liabilities | 41.08 M | 13.32 M | 14.98 M | 10.67 M |
| Total Liabilities | 114.46 M | 13.32 M | 14.98 M | 10.67 M |
| Shareholder's Equity | 97.52 M | 129.91 M | 127.49 M | 63.06 M |
| Outstanding Stock | 237.88 M | 216.43 M | 196.58 M | 177.85 M |
| Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | |
|---|---|---|---|---|
| Total Current Assets | 216.46 M | 152.63 M | 186.78 M | 211.69 M |
| Cash & Cash Equivalents | 182.85 M | 122.88 M | 161.61 M | 190.00 M |
| Total Assets | 246.55 M | 181.89 M | 211.98 M | 236.75 M |
| Total Current Liabilities | 41.88 M | 44.97 M | 41.08 M | 29.28 M |
| Total Liabilities | 238.46 M | 121.20 M | 114.46 M | 102.54 M |
| Shareholder's Equity | 8.09 M | 60.69 M | 97.52 M | 134.22 M |
| Outstanding Stock | 241.22 M | 241.16 M | 237.88 M | 216.83 M |
in USD
| Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | |
|---|---|---|---|---|
| Net Cash Flow from Operations | -106.81 M | -76.16 M | -69.14 M | -79.04 M |
| Capital Expenditures | -217,040.00 | -61,817.00 | -396,154.00 | -165,257.00 |
| Net Cash Flow from Investing Activities | -21.50 M | -827,108.00 | -1.26 M | -584,361.00 |
| Net Cash Flow from Financial Activities | 162.79 M | 72.58 M | 137.23 M | 92.97 M |
| Free Cash Flow | -107.03 M | -76.22 M | -69.54 M | -79.21 M |
| Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | |
|---|---|---|---|---|
| Net Cash Flow from Operations | -50.51 M | -76.16 M | -69.14 M | -79.04 M |
| Capital Expenditures | -830,086.00 | -262,418.00 | -150,745.00 | -20,575.00 |
| Net Cash Flow from Investing Activities | -1.21 M | -665,914.00 | -671,171.00 | -20.33 M |
| Net Cash Flow from Financial Activities | 111.69 M | 100,107.00 | 429,895.00 | 90.02 M |
| Free Cash Flow | -51.34 M | -38.43 M | -28.30 M | -34.09 M |
| Key Ratios | (Market Close Apr 19, 2021) | |||
|---|---|---|---|---|
| Valuation Ratios | 2021 | 2020 | 2019 | 2018 |
| P/E Ratio | -3.61 | -7.61 | -6.46 | -12.62 |
| Price to Sales Ratio | 33.74 | 72.13 | 53.25 | 98.88 |
| Price to Book Ratio | 9.29 | 10.06 | 8.90 | 29.25 |
| Enterprise Value to EBIT | -6.00 | -15.00 | -11.00 | -21.00 |
| Enterprise Value to EBITDA | -6.19 | -15.11 | -11.00 | -20.74 |
| Profitability Ratios | 2021 | 2020 | 2019 | 2018 |
| Revenue Growth | - | - | - | - |
| Net Income Growth | - | - | - | - |
| ROA | - | - | - | -71.30% |
| ROE | - | - | - | -127.30% |
| Liquidity Ratios | 2021 | 2020 | 2019 | 2018 |
| Working Capital | 145.70 M | 126.23 M | 124.43 M | 60.01 M |
| Current Ratio | 4.55 | 10.48 | 9.31 | 6.63 |
| Efficiency & Capital Structure Ratios | 2021 | 2020 | 2019 | 2018 |
| Debt Equity Ratio | 29.46 | 0.10 | 0.12 | 0.17 |
| Asset Turnover Ratio | - | - | - | 0.09 |
Scratchpad (max of 30 tickers)
| Symbol | Last Price | Change |
|---|---|---|
| Empty Scratchpad | ||
Portfolio (max of 30 tickers)
Login is required to view your portfolio.
